Table 2.

Adverse events during vedolizumab therapy.

Prospective cohort (n = 51)	CD patients (11 of 30)	UC patients (6 of 21)
Before week 14	IBD-related surgeries (n = 2)	Total proctocolectomy (n = 2)
	Histoplasmosis (n = 1)	Fever within 24h of first dose (n = 1)
	Anaphylaxis (n = 1)	Conjunctivitis (n = 1)
	Rash (n = 1)
After week 14	IBD-related surgeries (n = 4)	Total proctocolectomy (n = 1)
	Basal cell carcinoma (n = 1)	Diverting loop ileostomy (n = 1)
	CMV colitis followed by new Hodgkin's lymphoma diagnosis and subsequent death (n = 1)
Retrospective cohort (n = 115)	CD patients (2 of 34)	UC patients (2 of 30)
Before week 14		Total proctocolectomy (n = 2)
After week 14	IBD-related surgeries (n = 2)